Picture of Curacle Co logo

365270 Curacle Co Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+20.18%
3m+48.54%
6m+69.28%
1yr+67.54%
Volume Change (%)
10d/3m+249.5%
Price vs... (%)
52w High-14.66%
50d MA+28.07%
200d MA+54.46%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-17.64%
Return on Equity-26.32%
Operating Margin-102.08%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Curacle Co EPS forecast chart

Profile Summary

Curacle Co Ltd is a Korea-based company primarily engaged in the development of therapeutics for intractable vascular and metabolic diseases. The Company researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    May 12th, 2016
    Public Since
    July 22nd, 2021
    No. of Shareholders
    34,529
    No. of Employees
    34
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    kr flag iconKorea Exchange - KOSDAQ
    Shares in Issue
    13,855,342

    365270 Share Price Performance

    Upcoming Events for 365270

    Similar to 365270

    Picture of ABion logo

    ABion

    kr flag iconKorea Exchange - KOSDAQ

    Picture of ABL Bio logo

    ABL Bio

    kr flag iconKorea Exchange - KOSDAQ

    Picture of ADM Korea logo

    ADM Korea

    kr flag iconKorea Exchange - KOSDAQ

    Picture of Amicogen logo

    Amicogen

    kr flag iconKorea Exchange - KOSDAQ

    Picture of AprilBio Co logo

    AprilBio Co

    kr flag iconKorea Exchange - KOSDAQ

    FAQ